Company Profile

Abcam plc is a global life science company. The Company serves customers at the forefront of life science research through the identification, development, and distribution of biological reagents. Its products are used by researchers around the world to study biological pathways critical for scientific research, diagnostics, and drug discovery. It offers a selection of products in its catalogue to support research on proteins in biological pathways. Its principal catalogue product lines include primary and secondary antibodies, conjugated antibodies and conjugation kits, and singleplex immunoassays. It offers a range of peptides and proteins, which include cytokines, growth factors, and enzymes. It offers a range of knockout cell lines and lysates, which are used for its in-house validation needs and are also made available to its customers for their own research. It offers a variety of other products, including cellular activity kits, biochemicals and cell signaling pathway tools.

Employees

1,760

Sector

Pharmaceuticals

Calendar

2024-09-08 - Q2 2024 Earnings Release (Projected)

More about the company

Global markets live: Mastercard, Diageo, Nvidia, Airbnb, Exxon Mobil...	Dec. 06
Job losses delight investors	Dec. 06
Danaher Closes Acquisition of Abcam	Dec. 06	MT
Danaher completes $5.7 billion acquisition of Abcam	Dec. 06	RE
Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Composite Index	Dec. 06	CI
Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Biotechnology Index	Dec. 06	CI
Abcam plc(NasdaqGS:ABCM) dropped from S&P Global BMI Index	Dec. 06	CI
Danaher Corporation completed the acquisition of Abcam plc.	Dec. 05	CI
Abcam's Acquisition by Danaher Approved by UK Court	Dec. 04	MT
Abcam Says All Necessary Clearances for Acquisition by Danaher Obtained; Deal Set to be Completed on Dec. 6	Nov. 17	MT
All good things must come to an end	Nov. 07
Abcam Shareholders Approve Danaher's Acquisition Offer	Nov. 06	MT
Abcam shareholders approve $5.7 billion Danaher deal	Nov. 06	RE

RBC Trims Price Target on Abcam to $24 From $25, Keeps Sector Perform Rating	23-10-31	MT
SVB Securities Downgrades Abcam to Market Perform From Outperform, Price Target is $24	23-08-30	MT
Deutsche Bank Raises Abcam Price Target to $23.50 From $17, Maintains Hold Rating	23-08-28	MT
RBC Raises Abcam's Price Target to $25 From $22, Notes Strong Margin at H1; Keeps Sector Perform Rating	23-07-06	MT
RBC Downgrades Abcam to Sector Perform From Outperform, Trims Price Target to $22 From $23 After Recent Stock Jump, Sees 'Material Volatility'	23-06-20	MT

Danaher Completes Acquisition of Abcam	Dec. 06	PR
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales	Dec. 04	BU
Abcam Acquisition by Danaher has received all Identified Clearances, Transaction Expected to Close on December 6, 2023	Nov. 20	AQ
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023	Nov. 17	BU
Shareholders of Abcam Approve Proposed Acquisition by Danaher	Nov. 06	BU

Aktien New York Schluss: Weitere Erholung - Anleger warten auf Daten	23-08-28
MÄRKTE USA/Freundlich - Vor Konjunkturdaten wächst Zuversicht	23-08-28
Aktien New York: Erholungsschwung lässt nach	23-08-28
LATE BRIEFING - Unternehmen und Märkte	23-08-28
MÄRKTE USA/Gewinne bröckeln - Konjunkturdaten rücken in den Blick	23-08-28

Director	Title	Age	Since
Alan Hirzel CEO	Chief Executive Officer	56	13-08-04
Markus Lusser PSD	President	-	Mar. 17
Michael Baldock DFI	Director of Finance/CFO	60	20-02-02

Abcam plc Stock

Equities

ABCM

US0003802040

Pharmaceuticals

Chart: Abcam plc

Latest news: Abcam plc

Analysts' recommendations: Abcam plc

Press Releases: Abcam plc

News in other languages: Abcam plc

Managers and Directors: Abcam plc

ETFs: Abcam plc

Biopharmaceuticals

Company Profile

Name	Weight	AuM	1st Jan change	Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	0.82%	2 M€	-.--%
BMO MSCI INNOVATION INDEX ETF - CAD	0.29%	7 M€	-.--%	-
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.27%	0 M€	0.00%	-
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.25%	0 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
CSL LIMITED	+0.29%	-1.03%	+12.09%	-0.59%	98.59B
SAMSUNG BIOLOGICS CO.,LTD.	-1.16%	-2.20%	+27.04%	-1.68%	49.83B
UCB	-0.44%	-2.93%	+93.07%	+61.62%	33.57B
BIOGEN INC.	-1.54%	-1.47%	-24.22%	-39.51%	29.39B
BIOMARIN PHARMACEUTICAL INC.	-5.27%	-6.84%	-6.19%	+0.20%	16.21B
INCYTE CORPORATION	-2.13%	-4.48%	-0.51%	-17.26%	12.13B
ALTEOGEN INC.	-0.16%	-2.69%	+619.81%	+332.90%	12.21B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	+0.93%	-1.49%	+39.00%	-27.94%	12.38B
SWEDISH ORPHAN BIOVITRUM AB	+0.36%	-3.75%	+40.84%	+26.48%	10.26B
Average	-1.01%	-3.52%	+88.99%	+37.14%	30.51B
Weighted average by Cap.	-0.68%	-2.91%	+48.50%	+16.57%

Manager	Title	Age	Since
Alan Hirzel CEO	Chief Executive Officer	56	13-08-04
Mara Aspinall BRD	Director/Board Member	61	15-09-13
Giles Kerr BRD	Director/Board Member	65	18-12-11